Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors
Tools
Tools
Meredith, Erik, Ardayfio, Ophelia, Beattie, Kimberley, Dobler, Markus, Enyedy, Istvan, Gaul, Christoph, Hosagrahara, Vinayak, Jewell, Charles, Koch, Keith, Lee, Wendy, Lehmann, Hansjoerg, McKinsey, Timothy, Miranda, Karl, Pagratis, Nikos, Pancost, Margaret, Patnaik, Anup, Plato, Craig, Qian, Ming, Rajaraman, Vasumathy, Rao, Chang, Rozhitskaya, Olga, Ruppen, Thomas, Shi, Jie, Siska, Sarah, Springer, Clayton, Van Eis, Maurice, Vega, Richard, Von Matt, Anette, Yang, Lihua, Yoon, Taeyoung, Zhang, Ji, Zhu, Na and Monovich, Lauren (2010) Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors. Journal of Medicinal Chemistry, 53 (15). pp. 5400-5421. ISSN 0022-2623
Abstract
A novel 2,6-naphthyridine was identified by high throughput screen (HTS) as a dual protein kinase C/D (PKC/PKD) inhibitor. PKD inhibition in the heart was proposed as a potential anti-hypertrophic mechanism with application as a heart failure therapy. As PKC was previously identified as the immediate upstream activator of PKD, PKD vs. PKC selectivity was essential to understand the effect of PKD inhibition in models of cardiac hypertrophy and heart failure. The present study describes the modification of the HTS hit to a series of prototype pan-PKD inhibitors with routine 1000-fold PKD vs. PKC selectivity. Example compounds inhibited PKD activity in vitro, in cells, and in vivo following oral administration. Their effects on heart morphology and function are discussed herein.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | archiving not formally supported by this publisher |
| Keywords: | PKD, protein kinase D, cardiac, hypertrophy, HDAC, heart failure |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:16 |
| Last Modified: | 13 Oct 2015 13:16 |
| URI: | https://oak.novartis.com/id/eprint/2127 |